Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
pharmaphorum4d
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases
Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine ...
pharmaphorum3d
Alexion finally has a buyer – and it's AstraZeneca with $39bn on the table
Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...
Alexion’s ravulizumab granted FDA orphan designation
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
Hosted on MSN1y
FDA grants approval for Alexion’s NMOSD treatment
The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...
The Pharma Letter17h
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
Fortune2y
Alexion Pharmaceuticals
© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Nature4y
At Alexion, people living with rare diseases are our inspiration and our Guiding Star
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.
Hosted on MSN4mon
Pharmaceutical giant addresses critical health issue by rethinking its delivery trucks: 'Another milestone'
The global transportation and shipping sectors are responsible for large amounts of dirty pollution. To address this impact, pharmaceutical giant Alexion is partnering with global transportation ...